Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax

Figure 2

Hemoglobin recorded during Venetoclax monotherapy treatment from December 2018 to January 2020. The treatment initially began on November 28, 2018 at 100 mg and after one month was increased to 200 mg.